PARP16

Across TCGA pan-cancer cohorts, PARP16 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PARP16 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PARP16 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PARP16 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where PARP16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.510	0.729	.010	29	view →
PDAC	DFS	Tertile	All	0.357	0.784	.027	11	view →
LSCC	OS	Median	II,III,IV	1.000	0.884	.020	6	view →
UCEC	DFS	Tertile	All	0.789	1.000	.010	6	view →
CCRCC	DFS	Tertile	II,III,IV	0.734	0.435	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PARP16–HNSC (DFS)

Open the HNSC breakdown →